awmsg logo



talazoparib (Talzenna®)


Reference No. 2451

Publication date:
29/11/2019


Appraisal information

talazoparib (Talzenna®) 0.25 mg hard capsule
talazoparib (Talzenna®) 1 mg hard capsule


Company: Pfizer Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 28/11/2019

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, talazoparib (Talzenna®) cannot be endorsed for use within NHS Wales as monotherapy for the treatment of adult patients with germline BRCA1 or 2 mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo) adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy
Statement of Advice (SOA)
Download